{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:20Z","timestamp":1792723100410,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","revespcardiol.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.rec.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:35:58Z","timestamp":1789860958000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spanish founder variant in MYBPC3: implications of diagnostic criteria, clinical phenotype, and prognosis"],"prefix":"10.1016","author":[{"given":"Angel","family":"J\u00fadez-Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Wagih-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Sonicheva-Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Bezzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Sabater-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan R.","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2026.08.009_bib0265","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0300-8932(08)75730-0","article-title":"From Teare to the Present Day: A Fifty Year Odyssey in Hypertrophic Cardiomyopathy, a Paradigm for the Logic of the Discovery Process","volume":"61","author":"McKenna","year":"2008","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0270","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliot","year":"2014","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2026.08.009_bib0275","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0280","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.jacc.2016.08.079","article-title":"Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy","volume":"68","author":"Burke","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0285","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0290","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-genom-083118-015306","article-title":"Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies","volume":"20","author":"Yotti","year":"2019","journal-title":"Annu Rev Genomics Hum Genet."},{"key":"10.1016\/j.rec.2026.08.009_bib0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310510","article-title":"An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy","volume":"24","author":"Tudurachi","year":"2023","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.rec.2026.08.009_bib0300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/CIRCRESAHA.109.202440","article-title":"Evidence From Human Myectomy Samples That MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy Through Haploinsufficiency","volume":"105","author":"Marston","year":"2009","journal-title":"Circ Res."},{"key":"10.1016\/j.rec.2026.08.009_bib0305","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF03091771","article-title":"Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands","volume":"18","author":"Christiaans","year":"2010","journal-title":"Neth Heart J."},{"key":"10.1016\/j.rec.2026.08.009_bib0310","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jacc.2024.10.082","article-title":"Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis","volume":"85","author":"Shiwani","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0315","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0735-1097(03)00941-0","volume":"42","author":"Maron","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0320","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4065\/81.4.459","article-title":"Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations","volume":"81","author":"Binder","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.rec.2026.08.009_bib0325","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/hrt.77.2.130","article-title":"Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families","volume":"77","author":"McKenna","year":"1997","journal-title":"Heart."},{"key":"10.1016\/j.rec.2026.08.009_bib0330","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2024.11.030","article-title":"A More Accurate Diagnosis of Hypertrophic Cardiomyopathy: Simplifying the Complex Through Use of AI Technologies","volume":"85","author":"McKenna","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0335","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jmoldx.2012.04.001","article-title":"Resequencing the Whole MYH7 Gene (Including the Intronic Promoter, and 3\u2032 UTR Sequences) in Hypertrophic Cardiomyopathy","volume":"14","author":"Coto","year":"2012","journal-title":"The Journal of Molecular Diagnostics."},{"key":"10.1016\/j.rec.2026.08.009_bib0340","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ahj.2013.07.029","article-title":"Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy","volume":"166","author":"Marsiglia","year":"2013","journal-title":"Am Heart J."},{"key":"10.1016\/j.rec.2026.08.009_bib0345","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.recesp.2017.01.010","article-title":"Clinical and Genetic Diagnosis of Nonischemic Sudden Cardiac Death","volume":"70","author":"Jim\u00e9nez-J\u00e1imez","year":"2017","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0350","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2024-002891","volume":"11","author":"Melendo-Viu","year":"2024","journal-title":"Open Heart."},{"key":"10.1016\/j.rec.2026.08.009_bib0355","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2020.06.011","article-title":"Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers","volume":"76","author":"Lorenzini","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0360","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/jmedgenet-2012-101270","article-title":"Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing","volume":"50","author":"Lopes","year":"2013","journal-title":"J Med Genet."},{"key":"10.1016\/j.rec.2026.08.009_bib0365","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.recesp.2016.06.025","article-title":"A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain","volume":"70","author":"Sabater-Molina","year":"2017","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0370","first-page":"1980","article-title":"Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy","volume":"96","author":"Oliva-Sandoval","year":"2010","journal-title":"Findings from 18 Spanish families with a single mutation in MYBPC3. Heart."},{"key":"10.1016\/j.rec.2026.08.009_bib0375","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jacc.2005.05.087","article-title":"Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese","volume":"46","author":"Kubo","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0380","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","article-title":"Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy","volume":"342","author":"Spirito","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2026.08.009_bib0385","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2026.08.009_bib0390","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001002","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population","volume":"3","author":"Siontis","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.rec.2026.08.009_bib0395","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/CIRCULATIONAHA.114.011207","article-title":"Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation","volume":"130","author":"Adalsteinsdottir","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2026.08.009_bib0400","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0022-2828(03)00050-6","article-title":"Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy","volume":"35","author":"Waldm\u00fcller","year":"2003","journal-title":"J Mol Cell Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0405","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2350-13-105","article-title":"A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death","volume":"13","author":"Teirlinck","year":"2012","journal-title":"BMC Med Genet."},{"key":"10.1016\/j.rec.2026.08.009_bib0410","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/07853890.2012.671534","article-title":"Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population","volume":"45","author":"J\u00e4\u00e4skel\u00e4inen","year":"2013","journal-title":"Ann Med."},{"key":"10.1016\/j.rec.2026.08.009_bib0415","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCRESAHA.122.321956","article-title":"Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM","volume":"132","author":"Pioner","year":"2023","journal-title":"Circ Res."},{"key":"10.1016\/j.rec.2026.08.009_bib0420","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.recesp.2018.01.029","article-title":"Insights Into Hypertrophic Cardiomyopathy Evaluation Through Follow-up of a Founder Pathogenic Variant","volume":"72","author":"Lorca","year":"2019","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0425","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001789","article-title":"Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males","volume":"8","author":"M\u00e9ndez","year":"2021","journal-title":"Open Heart."},{"key":"10.1016\/j.rec.2026.08.009_bib0430","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/jmedgenet-2014-102923","article-title":"A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life","volume":"52","author":"Calore","year":"2015","journal-title":"J Med Genet."},{"key":"10.1016\/j.rec.2026.08.009_bib0435","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12265-024-10551-5","article-title":"Clinical Outcome of Hypertrophic Cardiomyopathy in Probands with the Founder Variant c.913_914del in MYBPC3: A Slovenian Cohort Study","volume":"18","author":"Vodnjov","year":"2025","journal-title":"J Cardiovasc Transl Res."},{"key":"10.1016\/j.rec.2026.08.009_bib0440","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2026.08.009_bib0445","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.002929","article-title":"Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy","volume":"13","author":"Helms","year":"2020","journal-title":"Circ Genom Precis Med."},{"issue":"Suppl 12","key":"10.1016\/j.rec.2026.08.009_bib0450","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0735-1097(25)01997-7","article-title":"Differences in patient characteristics and burden of disease in adults with MYBPC3-associated HCM","volume":"85","author":"Wang","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0455","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/hrt.2005.068577","article-title":"Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy","volume":"92","author":"Elliott","year":"2005","journal-title":"Heart."},{"key":"10.1016\/j.rec.2026.08.009_bib0460","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/cvr\/cvaf200","article-title":"First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1","volume":"121","author":"Desai","year":"2025","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.rec.2026.08.009_bib0465","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rec.2026.08.009_bib0470","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0475","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"The Lancet."},{"key":"10.1016\/j.rec.2026.08.009_bib0480","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem."},{"key":"10.1016\/j.rec.2026.08.009_bib0485","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41598-022-26630-z","article-title":"Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy","volume":"13","author":"Sharpe","year":"2023","journal-title":"Sci Rep."},{"key":"10.1016\/j.rec.2026.08.009_bib0490","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0495","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","article-title":"Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design Rationale, and Baseline Characteristics of ODYSSEY-HCM","volume":"13","author":"Desai","year":"2025","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.rec.2026.08.009_bib0500","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.jacc.2016.08.079","article-title":"Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy","volume":"68","author":"Burke","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2026.08.009_bib0505","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat Genet."},{"key":"10.1016\/j.rec.2026.08.009_bib0510","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41588-020-00762-2","article-title":"Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect","volume":"53","author":"Tadros","year":"2021","journal-title":"Nat Genet."},{"key":"10.1016\/j.rec.2026.08.009_bib0515","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41588-025-02087-4","article-title":"Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy","volume":"57","author":"Tadros","year":"2025","journal-title":"Nat Genet."},{"key":"10.1016\/j.rec.2026.08.009_bib0520","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41588-025-02094-5","article-title":"Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings","volume":"57","author":"Zheng","year":"2025","journal-title":"Nat Genet."}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585726002100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585726002100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:54:54Z","timestamp":1792720494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585726002100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"alternative-id":["S1885585726002100"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2026.08.009","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spanish founder variant in MYBPC3: implications of diagnostic criteria, clinical phenotype, and prognosis","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Cardiolog\u00eda.","name":"copyright","label":"Copyright"}]}}